PPARδ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Sucrose is used in prepared foods (e.g., cookies and cakes), is added to commercially available ultra-processed food and beverages, and is used as a sweetener for foods (e.g., toast and cereal) and beverages (e.g., coffee and tea). Globally, on average, a person consumes about 24 kilograms (53 pounds) of sugar each year. North and South Americans consume up to 50 kg (110 lb), and Africans consume under 20 kg (44 lb). The use of added sugar in food and beverage manufacturing is a concern for elevated calorie intake, which is associated with an increased risk of several diseases, such as obesity, diabetes and cardiovascular disorders. In 2015 the World Health Organization recommended that adults and children should reduce their intake of free sugars to less than 10% of their total energy intake, encouraging a reduction to below 5%.
==== Predictors of greater weight loss ==== Patient selection is an important consideration for any weight loss therapy. The present published literature shows either no influence or conflicting results for patient age, sex, starting weight/BMI on weight loss from ESG. Long-term after care programs have demonstrated benefit for sustained weight loss after ESG, with one study showing that patients who continued after care visits following ESG had 20.5% total body weight loss compared to 16.9% total body weight loss in those who dropped out of long-term follow up programs.
== Behavior and diet == It is a secretive species and is seldom encountered by humans. It is active by day and night, though it is usually more active by day. This largely aquatic snake spends most of its time in the water. It is an excellent swimmer and is capable of remaining underwater for up to 10 minutes and diving to depths of 25 m (82 ft). It is a slow mover on land, and it tends to hide among rocks, in holes, or overhanging tree roots at the shoreline. It also makes use of any man-made structures, such as bridges and jetties, to hide. It is generally not aggressive, and if approached in water, it will swim away swiftly and on land will attempt to escape into water. If threatened on land, it will rear up and spread its narrow, yet prominent hood and it may hiss loudly, but it tends not to make any forward movements. It will only bite when provoked. It preys almost exclusively on fish. It may also prey on frogs, toads, and other amphibians.
Sources: en.wikipedia.org
Topical gels are commonly used as sustained release dosage forms. Usage of the sustained release dosage form reduces the administration of recurrent doses while maintaining serum dose levels within the therapeutic range (the range between the minimum effective dose and the minimum toxic dose), hence improving patient compliance. Some topical gels are fast release gels, which are highly absorbent and can swell rapidly. These fast release gels can be used to treat acute disorders. Topical gels are also used as lubricants, or carriers for pharmaceutical agents. They can be used as vehicles for different purposes, via different routes of administration, such as dental, dermatologicall, ophthalmic, intranasal, vaginal, rectal and others. Topical gels are commonly used in cosmetics, which include shampoos, dentifrices, skin and hair care formulations and fragrance products, and can be used to treat scalp inflammation. Topical gels can be used to deliver anti-inflammatory steroids to the scalp in treatment of scalp inflammations.
Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes (artificial lipid bilayer vesicles) coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body. The antibody modified liposomes target tissue through cell-specific antibodies with the release of drugs contained within the assimilated liposomes. Immunoliposome aims to improve drug stability, personalize treatments, and increased drug efficacy. This form of therapy has been used to target specific cells, protecting the encapsulated drugs from degradation in order to enhance their stability, to facilitate sustained drug release and hence to advance current traditional cancer treatment.
Mass spectrometry Macromolecular crystallography Neutron diffraction Proteolysis Nuclear magnetic resonance spectroscopy of proteins (NMR) Electron paramagnetic resonance (EPR) Cryogenic electron microscopy (cryoEM) Electron crystallography and microcrystal electron diffraction Multiangle light scattering Small angle scattering Ultrafast laser spectroscopy Anisotropic terahertz microspectroscopy Two-dimensional infrared spectroscopy Dual-polarization interferometry and circular dichroism Most often researchers use them to study the "native states" of macromolecules. But variations on these methods are also used to watch nascent or denatured molecules assume or reassume their native states. See protein folding. A third approach that structural biologists take to understanding structure is bioinformatics to look for patterns among the diverse sequences that give rise to particular shapes. Researchers often can deduce aspects of the structure of integral membrane proteins based on the membrane topology predicted by hydrophobicity analysis. See protein structure prediction.
Consumption of fruit, nectar, pollen and other plant material occurs in megabats and New World leaf-nosed bats. Bats prefer ripe fruit and typically pull it from a tree and travel somewhere else to feed, possibly to avoid predators, though larger megabats may eat on site at the fruiting tree. The Jamaican fruit bat (Artibeus jamaicensis) has been recorded carrying fruit weighing as much as 50 g (1.8 oz). Many species of plants depend on bats for seed dispersal. Fruit-eating bats sometimes chew leaves to suck up the moisture and then spit them out. Bats apparently cannot digest cellulose. Nectar-eating bats have acquired specialised adaptations. These bats possess long muzzles and long, extensible tongues covered in fine bristles that aid them in feeding on particular flowers and plants. The tube-lipped nectar bat (Anoura fistulata) has a proportionally longer tongue than any mammal and is the only species capable of reaching deep into the flowers of Centropogon nigri. When the tongue retracts, it is pulled inside the rib cage. Because of these features, nectar-feeding bats cannot easily turn to other food sources in times of scarcity, making them more at risk of extinction than other species. Nectar feeding also aids a variety of plants, since these bats serve as pollinators, as pollen attaches to their fur while they feed. Around 500 species of flowering plant rely on bat pollination and thus tend to open their flowers at night. Many rainforest and Mediterranean plants depend on bat pollination.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.